Clinical Trial Update: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 [Phase 3]

View source ↗

Summary

Phase 3 study update of RC48-ADC for locally advanced or metastatic breast cancer with low HER2 expression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Breast Cancer | Phase 3 | Status: UNKNOWN